Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4918537 | 0.88 | TP53 (0.50) | TP53HSP90AA1KMT2AF2HPGD | |
| SCHEMBL4927290 | 0.78 | SIRT2 (0.48) | MAPK1TP53HSP90AA1KMT2AF2 | |
| SCHEMBL3724224 | 0.75 | CA12 (0.43) | KMT2AMAPTHSD11B1 | |
| SCHEMBL4927307 | 0.74 | SMN1; SMN2 (0.40) | TP53KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7386917 | 0.73 | TP53 (0.57) | TP53F2HPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4917411 | 0.71 | STAT3 (0.53) | TP53HSP90AA1KMT2AF2HPGD | |
| SCHEMBL1858551 | 0.71 | MAPT (0.41) | MAPK1TP53KMT2AALDH1A1MAPT | |
| SCHEMBL1859873 | 0.70 | TP53 (0.42) | TP53KMT2AF2ALDH1A1MAPT | |
| SCHEMBL1862225 | 0.69 | KMT2A (0.43) | MAPK1KMT2AF2SMN1; SMN2ALDH1A1 | |
| SCHEMBL13932919 | 0.68 | CACNA1B (0.50) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008098103-A1 | METHOD FOR PREPARING HALOGENATED AMINES | WYETH (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080188659-A1 | Method for Preparing Halogenated Amines | WYETH (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188659-A1 | Method for Preparing Halogenated Amines | PNMT, ABL1, INMT | MAPK1 3824/4885TP53 3224/4885HSP90AA1 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.